An anonymous director reports

SIRONA BIOCHEM ANNOUNCES PAYMENT OF CONVERTIBLE DEBENTURE INTERESTS IN SHARES

Pursuant to the 12-per-cent unsecured, convertible debentures in the principal amount of $1.5-million previously issued on April 20, 2023, Sirona Biochem Corp. will issue common shares in the capital of the company in satisfaction of interest payments on the outstanding debentures.

The company will issue an aggregate of 1,380,979 common shares at 6.75 cents based on closing price of nine cents on Oct. 19, 2023, with 25-per-cent maximum discounted applied per common share to holders of the debentures in satisfaction of an aggregate of $93,216 in interest payable as of Oct. 20, 2023.

Issuance of the common shares is subject to a number of conditions, including receipt of all necessary corporate and regulatory approvals, including the TSX Venture Exchange.

All securities issued in connection with the interest payment will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and continuing royalty payments. Sirona's laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants.

We seek Safe Harbor.